US Biopharmaceutical giant Amgen has announced a significant investment of €100 million in Portugal, aimed at establishing a new hub that will create 300 new jobs over the next few years.
Key Takeaways
- Amgen is investing €100 million in a new hub in Lisbon, Portugal.
- The investment will create 300 new jobs over the next two to three years.
- The Amgen Capability Center Portugal (ACCP) has already hired 170 employees in its first year.
- The center will support Amgen’s global business with a focus on high skill and innovation.
- The project has been recognized as a Project of Strategic Interest for the Lisbon economy.
Investment Details
Amgen’s €100 million investment will be spread over five years, focusing on the establishment and growth of the Amgen Capability Center Portugal (ACCP) in Lisbon. The center aims to support the overall business of the pharmaceutical company by leveraging local and international talent.
Job Creation
In its first year of operation, the ACCP has already hired 170 employees. The goal is to increase this number to 300 within the next two to three years. These employees will be involved in various high-skill and innovative roles that are crucial for Amgen’s global operations.
Strategic Importance
The project has been recognized as a Project of Strategic Interest for the Lisbon economy by the Institute of Employment and Professional Training (IEPF). This recognition underscores the importance of the investment for both Amgen and the local economy.
Why Portugal?
Daniel Campanha, the General Manager of the Amgen Capability Center Portugal, highlighted several reasons for choosing Lisbon over other European cities. These include the availability of qualified local talent, the ability to attract international talent, a positive cultural environment, and a suitable cost profile.
About Amgen
Amgen, formerly known as Applied Molecular Genetics Inc., is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company operates in approximately 100 countries and focuses on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. Amgen is known for developing medicines that address conditions with limited treatment options or provide viable alternatives to existing treatments.
Sources
- Amgen invests €100 million in Portugal – Essential Business, – Essential Business.
 will support the company's global business with a focus on high skill and innovation.){kind=link}